Abstract
Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.
Original language | English |
---|---|
Pages (from-to) | 243-248 |
Number of pages | 6 |
Journal | Annals of Gastroenterology |
Volume | 29 |
Issue number | 3 |
DOIs | |
State | Published - 2016 |
Keywords
- Biologics
- Crohn’s disease
- Inflammatory bowel disease
- Therapy
- Ulcerative colitis